Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd, an Australian biotechnology firm, is set to conduct an investor webinar discussing advancements in its iNKT cell therapy platform, following a successful pre-IND meeting with the FDA and progress in their CAR-iNKT manufacturing process. The webinar, led by CEO Dr. Michael Baker, will outline next steps for the company’s lead product, ALA-101, targeting CD19-positive blood cancers. Interested parties can register for the event scheduled for September 18, 2024, with the recording to be accessible post-event on the company’s website and social media.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
